RYTM
Rhythm Pharmaceuticals Inc.

1,964
Mkt Cap
$6.4B
Volume
768,479.00
52W High
$116.00
52W Low
$45.91
PE Ratio
-32.04
RYTM Fundamentals
Price
$99.41
Prev Close
$95.89
Open
$95.46
50D MA
$102.50
Beta
1.04
Avg. Volume
553,428.39
EPS (Annual)
-$4.34
P/B
44.55
Rev/Employee
$459,809.19
Loading...
Loading...
News
all
press releases
Connor Clark & Lunn Investment Management Ltd. Buys 64,561 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Connor Clark & Lunn Investment Management Ltd. lifted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 127.7% in the second quarter, according to its most recent Form 13F...
MarketBeat·23h ago
News Placeholder
More News
News Placeholder
HC Wainwright Has Negative Estimate for RYTM FY2025 Earnings
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Stock analysts at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a report issued on...
MarketBeat·2d ago
News Placeholder
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $114.00 at Canaccord Genuity Group
Canaccord Genuity Group upped their target price on Rhythm Pharmaceuticals from $105.00 to $114.00 and gave the company a "buy" rating in a report on Monday...
MarketBeat·3d ago
News Placeholder
RYTM FY2025 EPS Estimate Decreased by Needham & Company LLC
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Analysts at Needham & Company LLC reduced their FY2025 earnings per share estimates for Rhythm Pharmaceuticals in a report released on...
MarketBeat·5d ago
News Placeholder
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) have been given a consensus rating of "Moderate Buy" by the sixteen ratings firms that are covering the firm, MarketBeat.com...
MarketBeat·6d ago
News Placeholder
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.89% and +2.11%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·17d ago
News Placeholder
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·18d ago
News Placeholder
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago

Latest RYTM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.